Skip Navigation

JNCI Journal of the National Cancer Institute 2000 92(1):4-5; doi:10.1093/jnci/92.1.4
© 2000 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Shoemaker, R. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shoemaker, R. H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 92, No. 1, 4-5, January 5, 2000
© 2000 Oxford University Press

EDITORIAL

Genetic and Epigenetic Factors in Anticancer Drug Resistance

Robert H. Shoemaker

Correspondence to: Robert H. Shoemaker, Ph.D., Screening Technologies Branch, Bldg. 431A, National Cancer Institute- Frederick Cancer Research and Development Center, Frederick, MD 21702-1201(e-mail: shoemaker@dtpax2.ncifcrf.gov).

A wide variety of genetic and epigenetic factors have been implicated as determinants of anticancer drug resistance. Some of these are listed in Table 1.Go The growing body of published information regarding the function of oncogenes, tumor suppressor genes, cell cycle checkpoints, intracellular signaling cascades, and mechanisms of apoptotic cell death is shifting the focus of research toward microenvironmental and epigenetic factors. In this issue of the Journal, Taylor et al. (1) add significantly to the knowledge of epigenetic factors by documenting the effect of . . . [Full Text of this Article]

REFERENCES


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
S. Najmi, R. Korah, R. Chandra, M. Abdellatif, and R. Wieder
Flavopiridol Blocks Integrin-Mediated Survival in Dormant Breast Cancer Cells
Clin. Cancer Res., March 1, 2005; 11(5): 2038 - 2046.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
B. Gu, L. Espana, O. Mendez, A. Torregrosa, and A. Sierra
Organ-selective chemoresistance in metastasis from human breast cancer cells: inhibition of apoptosis, genetic variability and microenvironment at the metastatic focus
Carcinogenesis, December 1, 2004; 25(12): 2293 - 2301.
[Abstract] [Full Text] [PDF]